On the stock market since 1996, it operates in the world of health and science. It has 16 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 17% a year on average.
Sales run at $2.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 43 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $29.3M against $2.0M in annual sales.
The stock sits at $0.0004. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 5.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, PBIO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PBIO is a high-risk stock — not yet profitable, and its future rides on its product catching on.